SOUTH SAN FRANCISCO, CA -- (MARKET WIRE) -- 06/13/2005 -- Theravance, Inc. (NASDAQ: THRX) announced today that GlaxoSmithKline (GSK) has enrolled the first subjects in a Phase 1 clinical study designed to assess the safety, tolerability and pharmacokinetics of Theravance’s investigational, inhaled bronchodilator, GSK656398 (formerly known as TD-5742), for the treatment of chronic obstructive pulmonary disease (COPD).
